Internship

Gene Editing Intern

23064-T-670-SBIO

Posted on 3/22/2023

ArsenalBio

ArsenalBio

201-500 employees

Develops programmable cell therapies for cancer

No salary listed

San Bruno, CA, USA

Category
Biology & Biotech
Data & Analytics
Required Skills
R
Data Analysis
Requirements
  • Your whole self
  • Coursework and/or lab-based training in molecular biology, immunology, protein engineering or a related field
  • Entrepreneurial behaviors demonstrated by agility, accountability, transparency, resourcefulness, and ability to get things done
  • Ability to quickly learn new skills and knowledge on the job, demonstrate productivity, and deliver high-quality results
  • Flexible mind with ability to think outside the box, creative approach to problem solving, and comfort in working with ambiguous data in an open-ended, exploratory process
  • Ability to perform as a team player
  • Some experience in cell engineering and gene delivery workflows and technologies
  • Familiarity with R or similar environments for pipelining of routine data analysis
  • Some knowledge of synthetic biology and immunology
Responsibilities
  • Contribute to gene editing research efforts to increase efficiency of T cell engineering
  • Develop and execute experimental plans, balanced for risk and resource intensiveness, and identify areas of opportunity based on literature and other considerations
  • Contribute to decision-making processes on project teams, ensuring clear documentation and robust data sharing

ArsenalBio focuses on developing programmable cell therapies to treat solid tumor cancers. Their approach involves reprogramming cells to enhance their ability to fight cancer. The company is in the clinical stage, meaning they are primarily engaged in research and development to bring these therapies to market. Their target clients are patients with solid tumor cancers, a significant segment of the cancer patient population. ArsenalBio aims to generate revenue through the commercialization of their therapies once they receive approval. The team consists of experts from various scientific fields and professionals with clinical and manufacturing backgrounds, all working together to create effective cancer treatments.

Company Size

201-500

Company Stage

Series C

Total Funding

$630M

Headquarters

San Francisco, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent $325 million funding boosts ArsenalBio's clinical development capabilities.
  • Partnerships with Thermo Fisher enhance ArsenalBio's manufacturing and technological capabilities.
  • Growing demand for personalized medicine aligns with ArsenalBio's programmable cell therapy focus.

What critics are saying

  • Emerging competition from companies like Allogene Therapeutics in CAR T-cell therapies.
  • High manufacturing costs may affect ArsenalBio's pricing and market competitiveness.
  • Regulatory scrutiny on gene-editing technologies could delay therapy approvals.

What makes ArsenalBio unique

  • ArsenalBio integrates CRISPR, synthetic biology, and machine learning for advanced cell therapies.
  • Their focus on solid tumors sets them apart in the CAR T-cell therapy space.
  • ArsenalBio's CITE technology enhances T-cell targeting and tumor microenvironment overcoming.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical, dental, & vision coverage

Virtual & telehealth options

Parental leave

Flexible work schedule

Flexible PTO

Mental health resources

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

2%
Arsenal Bio
Jan 6th, 2025
ArsenalBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

South San Francisco, Calif. - January 6, 2025 - Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Ken Drazan, M.D., ArsenalBio's CEO and Chairman, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2025, at 4 p.m. PST.

Bakersfield.com
Sep 16th, 2024
Nate Hardy to Join Arsenal Biosciences, Inc. as Chief Financial Officer

Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Nate Hardy will join its management team as Chief Financial Officer, effective October 7, 2024.

BioPharma Reporter
Sep 5th, 2024
ArsenalBio bags $325 million to develop CRISPR-engineered cell therapies

ArsenalBio bags $325 million to develop crispr-engineered cell therapies.

Arsenal Bio
Sep 4th, 2024
ArsenalBio Announces $325 Million Financing to Advance Programmable Cell Therapy Programs through Clinical Development • Arsenal Bio

Oversubscribed Series C welcomes multiple new investors South San Francisco, Calif. – September 4, 2024 – Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the close of an oversubscribed $325 million Series C financing round. The funding round included new […]

CityBiz
Sep 4th, 2024
T. Rowe Price Joins $325 Million Financing for ArsenalBio

T. Rowe Price joins $325 million financing for ArsenalBio.

INACTIVE